Track market-moving stories before they get noisy

General Dynamics to Webcast 2026 Second-Quarter Financial Results Conference Call PR Newswire RESTON, Va., July

SANTA MONICA, Calif.--(BUSINESS WIRE)--Snap Inc. (NYSE: SNAP) will hold its quarterly conference call to discuss second quarter 2026 financial results on Monday, August 3, 2026 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).A live webcast and replay of the conference call will be accessible on Snap Inc.'s Investor Relations website for at least 90 days at: http://investor.snap.com.About Snap Inc.Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to imp.

BOCA RATON, Fla.--(BUSINESS WIRE)--The GEO Group, Inc. (NYSE:GEO) ("GEO") will release its second quarter 2026 financial results on Thursday, August 6, 2026 before the market opens. GEO has scheduled a conference call and simultaneous webcast for 1:00 PM (Eastern Time) on Thursday, August 6, 2026. To participate in the teleconference, please contact one of the following numbers 5 minutes prior to the scheduled start time: 1-877-250-1553 (U.S.) 1-412-542-4145 (International) In addition, a live.

WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter.

Second Quarter 2026 Conference Webcast Details:

What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earnings.open-exchange.net/.
A live and archived webcast of the conference call will also be accessible from the Investor Relations section of Clover Health’s website at https://investors.cloverhealth.com/ for 12 months.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
[email protected]

Press Inquiries:
[email protected]

DALLAS--(BUSINESS WIRE)--Atmos Energy Corporation (NYSE: ATO) will host a conference call on Thursday, August 6, 2026, at 10 a.m. Eastern to review the company's Fiscal 2026 third quarter financial results. Atmos Energy will release these results on Wednesday, August 5, 2026, following the market close. To listen to the conference call, please dial either the toll-free or international number provided below. You may also listen to the call on the Atmos Energy website at www.atmosenergy.com. The.

, /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ZoomInfo Technologies Inc. ("ZoomInfo" or the "Company") (NASDAQ: GTM) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOOMINFO TECHNOLOGIES INC. (GTM), CLICK HERE BEFORE AUGUST 24, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 
The complaint filed alleges that, between November 3, 2025 and May 11, 2026, Defendants failed to disclose to investors that: (1) ZoomInfo's optimistic plan for continued growth was undermined by slowing seat-based demand, weakening upsells and customers revising decisions to purchase AI products and develop internal AI-driven go-to-market solutions, making ZoomInfo's 2026 full year revenue guidance increasingly unlikely to be met; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Arbitrum rose 13%, trading around the $0.085 mark. The ARB market is in an early-stage bullish breakout zone. Arbitrum’s recent statement highlights a major financial milestone: the official mainnet launch of the Robinhood Chain. Built using Arbitrum’s Orbit technology and secured by the Ethereum blockchain, this dedicated Layer 2 network bridges traditional retail finance with Web3, bringing millions of Robinhood users directly on-chain to trade tokenised real-world assets, stocks, and DeFi protocols. 

The launch establishes massive long-term utility for Arbitrum’s technology, routing a percentage of the network’s processing fees directly into the Arbitrum DAO treasury.  Despite this massive institutional adoption news, the token is heavily influenced by broader crypto market momentum. 

While immediate price momentum remains neutral, this integration shifts the macro outlook. It establishes Arbitrum as the premier institutional scaling infrastructure, setting a strong fundamental floor for whenever macro liquidity returns to the market.

At the time of writing, Arbitrum has gained by over 13%, trading within the $0.08567 zone. With its market cap settled at $545.53 million, the daily trading volume has skyrocketed by over 112.62%, reaching $123.86 million, as reported by the CoinMarketCap data. 

Is Arbitrum Set This Rally to Sustain? The four-hour price chart of Arbitrum exhibits bullish momentum, likely breaking above the resistance level of $0.086. If the uptrend sustains, the bulls could initiate the emergence of a golden cross and push the asset to climb and test a higher target at around $0.088.

In the case of the positive sentiment fading, the ARB price could instantly fall to the support at the $0.084 range. A continued correction on the downside might trigger its death cross to take place. Followed by that, the bears may pull the price back to its former low at $0.082.  

Looking at Arbitrum’s technical chart, the market is in a strong, early-stage bullish breakout zone. MACD is above the zero, showing the faster moving averages have crossed positive. It is proving that bullish momentum is firmly in control. Signal line at zero, confirming that the longer-term trend might shift from bearish to bullish.

Also, this suggests that the buyers have completely washed out the sellers. The upward momentum is strong enough to pull the entire lagging trend upward. 

In addition, the current market of the ARB is in the overbought territory, as the daily Relative Strength Index stays at 70.63. The asset has experienced a rapid, aggressive move upward. While highly bullish, stretching past 70 is fundamentally vulnerable to profit-taking. A temporary price pullback or a minor correction is increasingly likely.

For buyers, chasing the price carries high risk. Moreover, traders watch for the RSI line to curl back below 70 as the trigger that the short-term local top is in and a pullback has started.

Crypto Market Highlights

Bitcoin (BTC) Enters a Critical Zone: Will Buyers Fuel a Breakout or Surrender $60K?

Content Writer | Crypto Enthusiast | Bridging Literature and Blockchain

Key Highlights Gold surged more than 1%, recovering above the $4,100 threshold following a three-session decline Fresh military confrontations between the United States and Iran sparked renewed safe-haven buying Federal Reserve meeting minutes revealed division among officials regarding future interest rate decisions Rising energy costs are intensifying inflation concerns, potentially prolonging elevated interest rates The resilient U.S. dollar and hawkish Federal Reserve tone continue to limit gold’s upward momentum Precious metal prices staged an impressive recovery on Thursday, advancing more than 1% following three consecutive sessions of declines. Spot gold increased 1.14% to reach $4,123.91 per ounce, while futures contracts for gold rose 1.25% to settle at $4,132.95 per ounce.

Gold Aug 26 (GC=F) The resurgence occurred as market participants returned to gold’s traditional safe-haven properties amid renewed military confrontations between Washington and Tehran.

Middle East Military Tensions Boost Precious Metal Appeal The United States initiated additional military operations against Iran on Thursday, coming just hours after President Donald Trump announced the breakdown of ceasefire negotiations with Iranian leadership. The regional conflict has been intensifying since hostilities erupted in late February.

Tehran’s armed forces retaliated with strikes targeting what they identified as U.S. military installations in Kuwait and Bahrain. The Islamic Revolutionary Guards Corps issued warnings of additional attacks on American military assets throughout the Gulf region should Washington persist with its military operations.

This recent escalation has created turbulence across energy markets. Iranian assaults on vessels attempting to navigate through the Strait of Hormuz have driven crude oil prices upward, subsequently heightening concerns about energy-related inflationary pressures.

Higher oil prices complicate the Federal Reserve’s ability to implement interest rate reductions. This creates a challenging environment for gold, as declining rates typically support the non-interest-bearing asset while elevated rates diminish its attractiveness.

“Any surge in energy prices will strengthen market expectations that the Federal Reserve may maintain interest rates at elevated levels for an extended period to address persistent inflation,” noted analysts at ANZ in their research commentary.

Federal Reserve Meeting Minutes Reveal Policy Uncertainty The release of Federal Reserve minutes from June’s policy meeting provided markets with additional considerations. Central bank officials demonstrated disagreement regarding the necessity of additional interest rate increases, offering some encouragement to gold investors.

The prospect that rate increases might be suspended later this year contributed to improved sentiment surrounding bullion. Reduced borrowing costs decrease the opportunity cost associated with holding gold, which generates no yield.

However, the same meeting minutes also indicated that Fed policymakers are becoming increasingly worried about entrenched inflation. U.S. inflationary pressures have consistently exceeded the central bank’s 2% objective since the onset of the Iran conflict.

“The minutes confirm that the possibility of a September interest rate increase remains firmly on the table,” stated Thomas Ryan from Capital Economics.

The U.S. dollar remained relatively unchanged at 100.98 on Thursday but continues hovering near 13-month peak levels achieved in June. A robust dollar typically increases gold’s cost for international buyers using alternative currencies, which generally constrains demand.

Gold had experienced downward pressure earlier in the week as the dollar gained strength on inflation anxieties connected to the regional conflict. Thursday’s rally lifted gold back above the $4,100 threshold after Wednesday’s downturn pushed it beneath that psychological level.

Key Highlights Table of Contents

Key HighlightsMemory Chipmaker’s Public Offering Generates Intense InterestGeopolitical Tensions Fail to Derail RallyEconomic Data and Corporate EarningsGet 3 Free Stock Ebooks Technology stocks powered indices higher with the Nasdaq advancing 1.2%, S&P 500 up 0.8%, and Dow rising 0.4% Thursday Investor appetite for SK Hynix’s Friday Nasdaq listing reached seven times the number of shares being offered Military conflict between the U.S. and Iran intensified with American forces hitting 90 Iranian locations, prompting Iranian retaliation against allied targets Crude oil retreated Thursday, reversing part of the previous session’s advance despite Middle East hostilities PepsiCo earnings revealed weakening consumer demand as Americans tighten budgets, though overall sales exceeded analyst forecasts American equity markets posted solid advances Thursday, with technology shares leading the charge as market participants shrugged off geopolitical uncertainty and focused attention on SK Hynix’s upcoming artificial intelligence-focused public offering.

The tech-heavy Nasdaq Composite advanced 1.2%, while the benchmark S&P 500 climbed 0.8%. The blue-chip Dow Jones Industrial Average registered a more modest gain of approximately 0.4%.

Nasdaq 100 Sep 26 (NQ=F) The rally displayed widespread participation across market segments. The Equal Weight S&P 500 index surpassed its traditional market-cap-weighted counterpart, indicating the advance wasn’t confined to mega-cap technology names.

Three sectors bucked the upward trend: energy, consumer staples, and healthcare all finished lower. This sectoral breakdown is typical of risk-embracing sessions, with investors rotating away from traditionally defensive areas.

Memory Chipmaker’s Public Offering Generates Intense Interest Thursday’s bullish sentiment was largely fueled by enthusiasm surrounding SK Hynix, the South Korean semiconductor manufacturer specializing in memory chips. The company planned to finalize pricing Thursday evening before commencing trading on the Nasdaq Friday morning.

Investor appetite has proven remarkably robust, with subscription requests reaching seven times the available allocation—a clear indication of confidence in artificial intelligence infrastructure spending trajectories.

The offering arrives following a turbulent period for semiconductor equities. Recent weakness in chip stocks had prompted questions about the sustainability of the AI-fueled market advance.

Geopolitical Tensions Fail to Derail Rally Geopolitical developments commanded headlines Thursday. American military forces conducted operations against 90 Iranian sites, prompting Tehran to launch countermeasures against facilities in nations aligned with Washington throughout the Middle East region.

Despite the military escalation, equity investors displayed remarkable resilience. Markets maintained their positive trajectory throughout trading hours.

Oil prices declined Thursday, erasing portions of the prior day’s gains. The market response suggested traders anticipate continued tensions without necessarily expecting worst-case scenarios to materialize.

U.S. Treasury yields remained relatively unchanged. Currency markets showed similar stability, with the dollar exhibiting minimal movement.

Economic Data and Corporate Earnings Weekly unemployment insurance filings showed marginal variation from the previous period. The relatively stable employment picture continues informing investor expectations regarding Federal Reserve monetary policy trajectory.

PepsiCo delivered quarterly results Thursday morning. While topline revenue exceeded Wall Street estimates, company management highlighted increasing consumer caution as economic uncertainty weighs on household spending patterns.

Among constituents of the Roundhill Magnificent Seven ETF, Meta Platforms and Tesla delivered positive returns, partially counterbalancing declines from Nvidia and Alphabet.

The specialized ETF managed to close marginally higher after recovering from steeper intraday losses earlier in the session.

By mid-afternoon, the Nasdaq traded around 26,194, while the S&P 500 hovered near 7,546 and the Dow sat approximately at 52,550.

Western Digital Corp (NASDAQ:WDC) shares are moving higher Thursday as a pair of major developments stoke fresh enthusiasm across the memory chip space pulling storage and semiconductor names broadly higher.

Western Digital stock is among today’s top performers. What’s fueling WDC momentum? Micron’s $250 Billion U.S. Investment Commitment Lifts Memory NamesThe announcement reinforced the broader narrative that memory is becoming a critical bottleneck in the AI infrastructure buildout lifting names across the space including Western Digital.

Meta’s Computing Expansion is Fueling Memory DemandThe scale of Meta’s AI infrastructure ambitions is adding to concerns about memory supply tightness a dynamic that is broadly supportive of pricing and demand across the memory ecosystem.

WDC Shares Are SoaringWDC Price Action: Western Digital shares were up 5.74% at $581.87 at the time of publication on Thursday, according to Benzinga Pro.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Rocket Lab (RKLB 0.78%) is understandably getting a lot of attention from investors these days. The company is making big moves in the rocket-launch space and has recently made an important acquisition that could establish it as a key player in the satellite market. It's also on many people's radars, considering that it's increasingly becoming a competitor to Space Exploration Technologies.

Rocket Lab shares are up 118% over the past year, and while its share price has been volatile, there are some reasons why owning Rocket Lab stock could be a good long-term bet. Here's why.

Image source: Getty Images.

A formidable space launch and satellite company Rocket Lab is one of the largest rocket launch companies, providing launch services to its customers. The company just had one of its best quarters, with a record number of launch contracts ever -- the company signed 31 in Q1 2026. Rocket Lab sold more launches in the first quarter than it did in all of 2025.

In addition to record contracts, the company's financials were also impressive in the quarter. Sales rose nearly 64% in the quarter to $200 million, outpacing Wall Street's consensus estimate of about $189 million. The company's losses also narrowed to $0.07 per share, better than the consensus estimate of $0.08 per share, and up from a loss of $0.12 per share in the year-ago quarter.

While that growth has fueled considerable optimism for Rocket Lab, the company recently announced plans to buy Iridium Communications (IRDM +0.26%), which could propel its growth even higher. Iridium provides satellite-based mobile communications services to its 2.5 million subscribers across both private and government sectors.

The nearly $8 billion purchase (in a half-stock, half-cash deal) is expected to close in the first half of 2027 and will give Rocket Lab a significant position in the satellite communications industry -- all while maintaining its rocket launch business. Iridium is also profitable, generating more than $114 million in net earnings in 2025.

While Rocket Lab's business isn't as large as SpaceX's, owning Iridium will help Rocket Lab to compete with SpaceX's satellite and rocket launch business. And that's not its only space-based play, either.

Rocket Lab already has notable defense contracts with the U.S. government, including to help build a satellite system for its proposed Golden Dome missile defense system. And that's in addition to contracts it already has with the Space Development Agency (SDA), which are currently worth more than $1 billion for missile-tracking and military communications satellites.

Today's Change

(

-0.78

%) $

-0.65

Current Price

$

82.70

Lots of potential, but there are some risks for Rocket Lab With its Iridium acquisition, government contracts, rising sales, and overall position in the launch and satellite communications space, Rocket Lab is certainly worth your consideration right now.

But that doesn't mean the stock will be a guaranteed winner. Its shares can be very volatile, and any delay for its Neutron rocket, which will have its first test flight later this year, could cause investors to react negatively.

What's more, being a SpaceX competitor could be both a blessing and a curse. Rocket Lab could benefit when SpaceX and the general space industry are doing well, but negative news for SpaceX could make Rocket Lab shares more volatile in the short term.

And finally, investors need to be aware that Rocket Lab isn't profitable -- it lost $45 million in the first quarter -- and its shares trade at a price-to-sales ratio of 82, which is quite a premium. The tech sector P/S ratio average is 9.

Still, Rocket Lab appears to be worth at least some of the risk right now. The company is already a top player in the growing space launch and satellite communications industries. Starting a small position or adding to an existing one while shares are lower is probably a smart move.

, /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM) ("Iridium"), a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, will release its financial results for the second quarter of 2026 on Wednesday, July 22, 2026.

As previously announced on June 29, 2026, Iridium entered into a definitive agreement under which it will be acquired by Rocket Lab Corporation (Nasdaq: RKLB). Due to the pending transaction, the Company will not host a conference call to discuss its quarterly financial results.

Iridium's second-quarter 2026 earnings press release will be available on the investor relations page of the Company's website.

About Iridium Communications Inc.

Iridium Communications Inc. (Nasdaq: IRDM) operates the world's only truly global mobile satellite network. It serves as a platform for innovation, enabling voice, data, and messaging, positioning, navigation, and timing (PNT), and aircraft surveillance services anywhere on Earth. Through its satellite constellation and integrated capabilities like Aireon, the world's only space-based air traffic surveillance system, Iridium delivers services that support safety-focused operations across aviation, maritime, government, industrial, and consumer markets. The company is a leader in satellite Internet of Things (IoT) connectivity and is advancing direct-to-device (D2D) communications based on open standards to expand access to satellite services.

Headquartered in McLean, Virginia, Iridium innovates through an ecosystem of more than 500 technology and distribution partners, serving millions of customers worldwide. For more information visit www.iridium.com.

Investor Contact:
Kenneth Levy  
Iridium Communications Inc.
+1 (703) 287-7570
[email protected]

Press Contact:
Jordan Hassin
Iridium Communications Inc.
+1 (703) 287-7421
[email protected]

SOURCE Iridium Communications Inc.

Conference Call and Webcast Scheduled for Thursday, July 30

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026.

The schedule for the press release and conference call / webcast is as follows:

Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ET Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ET Domestic Dial-In Number: 800-347-6865 International Dial-In Number: 203-518-9757 Conference ID: NBIX The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)  

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

SOURCE Neurocrine Biosciences, Inc.

Energy prices are much higher in 2026. That’s good news for some investors. The Vanguard Energy ETF (VDE 1.36%) and Global X - MLP & Energy Infrastructure ETF (MLPX 0.69%) offer different ways to play the energy cycle, with VDE tracking diversified giants and MLPX focusing on midstream assets.

Both funds capitalize on recent energy sector momentum but approach the industry from different angles. This analysis compares the broad, equity-focused strategy of the Vanguard fund against the infrastructure-centric portfolio of the Global X fund to help you determine which fits your investment goals.

Snapshot (cost & size)MetricMLPXVDEIssuerGlobal XVanguardShare price$75.66 (as of 2026-07-08)$156.94 (as of 2026-07-08)Expense ratio0.45%0.09%1-yr return (as of 2026-07-08)29.80%30.10%Dividend yield4.00%2.70%Beta0.580.44AUM$3.5 billion$11.8 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

With an expense ratio of 0.09%, Vanguard Energy ETF is more affordable than Global X - MLP & Energy Infrastructure ETF, which charges 0.45%. However, the Global X fund offers a higher dividend payout.

Performance & risk comparisonMetricMLPXVDEMax drawdown (5 yr)(19.70%)(26.60%)Growth of $1,000 over 5 years (total return)$2,671.00$2,511.00What's insideVanguard Energy ETF focuses on the broad U.S. energy sector, including oil, gas, and consumable fuels, with approximately 99.5% energy exposure. Its largest positions include ExxonMobil Corp (XOM 2.70%) at 21.7%, Chevron Corp (CVX 1.09%) at 14.1%, and ConocoPhillips (COP 2.44%) at 5.8%. The fund maintains 111 holdings in total. It was launched in 2004. Vanguard Energy ETF has paid $4.03 per share over the trailing 12 months, which on its recent ~$156.94 share price works out to a 2.70% yield.

Global X - MLP & Energy Infrastructure ETF targets midstream infrastructure, specifically master limited partnerships and corporations, with 99% energy exposure. Its largest holdings include TC Energy (TRP 1.48%) at 9.1%, Enbridge (ENB 0.87%) at 8.9%, and The Williams Companies (WMB +0.29%) at 8.9%. The fund consists of 29 holdings. It was launched in 2013. Global X - MLP & Energy Infrastructure ETF has paid $3.04 per share over the trailing 12 months, which on its recent ~$75.66 share price works out to a 4.00% yield.

Which fund is the better buy?The Global X - MLP & Energy Infrastructure ETF — MLPX — focuses on the midstream portion of the energy business. Midstream businesses like pipelines tend to be less volatile because they are the least exposed to energy price fluctuations. Unlike traditional MLP funds, MLPX avoids fund-level taxes by limiting direct MLP exposure and investing in similar entities, such as the general partners of MLPs and other energy infrastructure corporations. That’s a plus for investors, since funds that hold MLPs can incur additional taxes for investors, even if they are simpler than directly investing in MLP stocks.

The Vanguard Energy ETF — VDE — invests in straightforward equities rather than MLPs, so it accesses a different segment of the energy business, primarily producers and retailers.

The Vanguard fund has had a better 52-week performance, reflecting the greater volatility in oil and gas producers and retailers, who respond much more readily to commodity price changes. Midstream energy businesses are more insulated from oil and gas price shocks because the fuels need to be transported regardless of price. But over time, the Global X fund shows its chops. MLPX has returned 27.1%, 21.2%, and 12% over the 3-year, 5-year, and 10-year periods. VDE has returned 13.4%, 18.7%, and 8.4% over the 3-, 5-, and 10-year lookbacks, respectively.

While MLPX has a higher expense ratio, its long-term performance is superior to VDE’s. For those looking to capitalize on higher energy prices in 2026, MLPX is the ETF to buy.

For more guidance on ETF investing, check out the full guide at this link.

Lumentum Holdings Inc. (NASDAQ:LITE) stock is trading higher on Thursday. The California-based technology firm is experiencing upward momentum alongside other companies in the fiber optic connectivity sector.

The Nasdaq is up 1.55% while the S&P 500 has gained 0.72%.

• Lumentum Holdings stock is surging to new heights today. Why are LITE shares rallying?

Sector Catalysts Boost Demand OutlookMeta declined to comment on the development following a Benzinga inquiry.

Infrastructure Expansions Signal Sustained AppetiteDecreasing Short Interest Supports UpsideMarket data indicates that short interest in Lumentum decreased during the latest reporting period, dropping from 10.22 million to 9.29 million shares. This short interest accounts for 13.22% of the company’s publicly available float. Based on an average daily trading volume of 6.21 million shares, short sellers would require 1.5 days to cover their positions.

LITE Stock: Key Levels and Momentum IndicatorsEven after today’s jump, Lumentum is still trading 5.3% below its 20-day SMA and 11.3% below its 50-day SMA, which keeps the near-term trend in "repair mode" despite the strong session. At the same time, the stock remains 42.1% above its 200-day SMA, so the longer-term uptrend is still intact even with recent volatility. RSI is the cleaner momentum read right now: at 46.23.

The moving-average structure is mixed, with the 20-day SMA below the 50-day SMA (a bearish near-term alignment) even as the 50-day SMA remains above the 200-day SMA (a bullish longer-term backdrop). That combination often produces sharp countertrend rallies that still need follow-through to flip the short-term trend back up.

Key Resistance: $809 — Nearby round-number area that also sits close to the 100-day SMA zone, where rebounds can stall. Key Support: $776 — Nearby pivot area just above the 100-day EMA, where buyers may try to defend the recent base. LITE Stock Price Activity: Lumentum stock was up 12.33% at $794.30 at the time of publication on Thursday, according to Benzinga Pro data.

Photo: Piotr Swat on Shutterstock.com

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Twelve thousand dollars a month sounds like a round number, but it carries weight. It works out to $144,000 a year, a little more than twice the U.S. per capita disposable personal income of $68,391 reported for the first quarter of 2026. Replacing that with portfolio income, rather than a paycheck, is a math problem before it is anything else. And the answer depends almost entirely on how much yield you are willing to reach for.

Every extra point of yield shrinks the capital pile you need. That is the appeal, and also the trap. With the 10-year Treasury recently around 4.5% and the federal funds target range upper limit at 3.75%, income is finally competitive again. But higher yield rarely comes free.

The Conservative Path: Roughly $4.1 Million At a 3.5% blended yield, $144,000 divided by 0.035 comes out to about $4,114,000. This is the dividend growth lane: broad dividend ETFs, dividend aristocrats, and mature consumer and healthcare names.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the archetype. The yield is only around 2%, but the board just approved a $1.34 quarterly dividend, up from $1.30, extending a 64-year streak of annual increases. Procter & Gamble (NYSE:PG) yields 2.9% and has raised its dividend for 70 consecutive years. Paired with higher-yielding dividend growth funds, the blended portfolio can land in the 3% to 4% range.

The tradeoff is capital intensity. You need the biggest nest egg here. What you get back is durability: diversification, principal that tends to appreciate, and a raise nearly every year without lifting a finger.

Stepping Up to 6% Yield: About $2.4 Million Shift the target yield to 6%, and $144,000 divided by 0.06 equals $2,400,000. That is nearly $1.7 million less in required capital, and it opens the door to REITs, midstream energy, preferred shares, and high-dividend equity funds.

Realty Income (NYSE:O) yields 5.2% and has paid 670 consecutive monthly dividends, with portfolio occupancy at 98.9%. Kinder Morgan (NYSE:KMI) yields 3.6%, backed by an $8.6 billion adjusted EBITDA budget for 2026 and a $10.1 billion project backlog that is 92% natural gas. Blend the two with preferred shares or a covered-call equity fund, and 5% to 7% is realistic.

What you give up is growth velocity. Realty Income’s monthly dividend rose from $0.269 to $0.271 over the past year, less than 1%. That is not going to outrun the Core PCE trend, which just hit its 12-month high.

Reaching for 10%: Around $1.44 Million Push the yield to 10%, and the capital requirement drops to $1,440,000. This tier is business development companies, mortgage REITs, leveraged covered-call funds, and high-yield bond funds.

Main Street Capital (NYSE:MAIN) illustrates the appeal. Between a $0.26 monthly regular dividend and 19 consecutive quarterly $0.30 supplementals, total distributions push the effective yield well above the regular 5.9% stated figure. Q4 return on equity was 18% annualized.

The catch: BDCs and mortgage REITs can cut distributions in credit downturns, and share prices often bleed lower over time. Main Street is down about 10% year to date. You are spending down the asset in a way you often are not at 3.5%.

The Insight the Yield Table Hides Compounding rewrites the story. A 3.5% yield that grows 8% annually doubles the income stream in about nine years. A 10% yield with no growth still pays the same nominal income, and that income buys less after inflation. The comparison is not that one approach is automatically better. It is that a lower-yielding portfolio with rising dividends may eventually catch up to a high-yield portfolio whose distributions stay flat or get cut.

What to Do Before You Commit Calculate your actual annual spending, not your gross income. Replacing $144,000 pre-tax may be replacing $95,000 in real outflows. The capital requirement drops fast when the target does. Model the tax impact in your bracket. Qualified dividends, REIT ordinary income, and BDC distributions are all taxed differently. A 10% yield in a taxable account often trails a 4% qualified-dividend yield in a Roth. Compare 10-year total return, not just yield, on any high-yield fund you are considering. If the price chart slopes down over a decade while distributions stay flat, you are being paid with your own money. The Yield Is the Price Tag A $12,000 monthly income target can require more than $4 million at conservative yields, about $2.4 million at 6%, or roughly $1.44 million at 10%. The math is simple. The risk tradeoff is not. Higher yield lowers the capital requirement by asking the portfolio to absorb more credit risk, leverage, volatility, tax complexity, or slower growth. The right portfolio is not the one with the smallest required nest egg. It is the one most likely to keep paying after the market stops cooperating.

Contact [email protected] for any questions or corrections.

WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation expects to report its second quarter earnings at the end of business on Thursday, July 23, 2026.

NEW YORK--(BUSINESS WIRE)---- $IFF--IFF (NYSE: IFF) today announced that it will release its second quarter 2026 earnings results following the market close on Tuesday, August 4, 2026. The management team will host a live webcast on Wednesday, August 5, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded.

The New York Times and The Daily News claim that OpenAI has been lying about its ability to search customer chat log data and training datasets for their copyrighted works. It’s the latest escalation in a two-year lawsuit against the AI firm for allegedly violating copyright law by training its generative AI models on the Times’ content and reproducing that journalism in user outputs.

Throughout the case, OpenAI has argued that it lacked the ability to search its own training corpus. It also argued that searching or producing its massive collection of ChatGPT conversations would be technically burdensome and would raise user-privacy concerns because the logs would need to be retrieved, processed, and de-identified. The outlets sought that data to determine whether their copyrighted journalism was present in OpenAI’s training dataset and whether and how often ChatGPT generated responses using or reproducing their content.

In an April court-ordered deposition, OpenAI data privacy engineer Vinnie Monaco allegedly revealed that OpenAI had already conducted internal searches and evaluations of its training corpus to search for copyrighted journalism works. 

Monaco’s deposition also allegedly revealed that, beginning before the NYT filed its lawsuit, OpenAI had already amassed a database of about 78 million de-identified ChatGPT conversations that it was using internally to determine how much it was infringing on others’ works. On top of that dataset, OpenAI also allegedly implemented a “Bloom” filter as part of a set of tools called “Project Giraffe,” which detected and kept a record of regurgitation in outputs, shortly after the lawsuit was filed. 

Those last two revelations are particularly significant. The plaintiffs had originally asked OpenAI to provide a sample of 120 million chat logs, but OpenAI had negotiated to bring the sample down to just 20 million. OpenAI finally submitted that sample to the courts last December, but it had allegedly included so many redactions as to render the sample “unusable,” in the court’s words. The plaintiffs also claimed OpenAI deleted billions of ChatGPT outputs after they filed suit in direct violation of the court’s preservation order, and that the AI giant substituted millions of logs in the requested sample. 

In other words, they claim OpenAI made it needlessly difficult to obtain information that the company had already collected.

“If OpenAI genuinely believed that copying our clients’ journalism was fair and legal, it wouldn’t have hid the truth about having done it,”  Ian B. Crosby, lead counsel for the plaintiffs, said in a statement.

Now, the NYT and The Daily News are asking the judge to discipline OpenAI for allegedly withholding evidence and messing with the discovery process. They are asking the court to prevent OpenAI from using the 20 million chat log sample as evidence, claiming it is unreliable; to accept as fact that ChatGPT logs would have shown major regurgitation and grounding of the plaintiffs’ content; to prevent OpenAI from arguing that its provided chat logs don’t demonstrate substantial regurgitation; and to make OpenAI pay legal fees for having to chase down this evidence. 

In a statement, OpenAI spokesperson Drew Pusateri denied the allegations, accusing the Times of trying to access private user conversations as its case weakens.

“As the Times’ case weakens and they’ve been forced to drop claims against us, they’re persisting with their efforts to invade the privacy of people who have nothing to do with this case, including by making these blatantly false allegations,” Pusateri said. “We’ll continue defending our users’ privacy and the long-established principles of fair use.”

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Rebecca Bellan is a senior reporter at TechCrunch where she covers the business, policy, and emerging trends shaping artificial intelligence. Her work has also appeared in Forbes, Bloomberg, The Atlantic, The Daily Beast, and other publications.

You can contact or verify outreach from Rebecca by emailing [email protected] or via encrypted message at rebeccabellan.491 on Signal.

Key Takeaways UTHR reported positive phase III results for Tyvaso in IPF, supporting a planned FDA supplemental filing.UTHR plans an FDA filing for ralinepag after phase III success & targets $4B annual revenue run rate by 2027.UTHR is advancing organ manufacturing while facing growing competition for its core PAH therapies. Shares of United Therapeutics (UTHR - Free Report) have gained 14% year to date against the industry’s 0.8% decline, driven by major clinical breakthroughs and improved long-term growth visibility that have significantly strengthened investor confidence.

Image Source: Zacks Investment Research

UTHR’s Meaningful Pipeline Expansion Encourages InvestorsInvestor sentiment has been boosted by encouraging progress across United Therapeutics' pipeline.

The company is expanding nebulized Tyvaso beyond its approved pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications into larger pulmonary fibrosis markets such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company's IPF development program consists of two pivotal phase III studies, TETON-1 and TETON-2. The studies share a similar design, differing primarily in their geographic scope. TETON-1 was conducted at sites across the United States and Canada, while TETON-2 enrolled patients at sites outside these countries.

In March 2026, the company announced positive results from the late-stage TETON-1 study, which achieved its primary endpoint by demonstrating a statistically significant improvement in lung function for patients with IPF. The magnitude of benefit observed in TETON-1 exceeded the already strong outcomes previously reported in TETON-2, representing a significant advancement for patients with IPF.

Positive phase III data from both the TETON-1 and TETON-2 studies support a planned FDA supplemental application for Tyvaso in IPF. Management believes the IPF opportunity alone could eventually surpass Tyvaso's current PAH revenues. It is also enrolling patients in the phase III TETON PPF study evaluating the drug in patients with PPF.

The company's late-stage PAH candidate ralinepag delivered positive phase III data from the ADVANCE OUTCOMES study in March. The study met its primary and secondary endpoints. UTHR intends to submit a new drug application for ralinepag to the FDA in the second half of 2026. 

The company is developing an inhaled dry-powder version of ralinepag (RAL-DPI) in collaboration with MannKind Corporation. While initially targeting PAH, management sees potential opportunities for RAL-DPI in PH-ILD, IPF and PPF.

Together, Tyvaso's label expansion and the ralinepag franchise are expected to drive long-term growth, supporting the company's goal of increasing its annual revenue run rate from $3 billion to $4 billion by the end of 2027 and boosting investor sentiment.

Organ Manufacturing Business on MoveUnited Therapeutics continues to strengthen its long-term growth outlook through steady progress in its organ manufacturing platform, which spans hearts, kidneys, livers and lungs. The company is advancing multiple technologies, including xenotransplantation, regenerative medicine, bioengineered organs, 3D bioprinting and ex-vivo lung perfusion (EVLP) to address the global shortage of donor organs.

Its xenotransplantation portfolio includes development-stage candidates UKidney, UHeart and UThymoKidney. The FDA cleared the investigational new drug application for the phase I EXPRESS study evaluating UHeart in May. United Therapeutics received FDA premarket approval for LungFX, the first EVLP device for assessing donor lungs outside the body, with a commercial launch planned for 2027.

Earlier this month, the acquisition of Thymmune Therapeutics expanded the company's regenerative medicine portfolio with the preclinical thymic cell therapy THY-100, strengthening its long-term strategy to improve organ transplantation and immune restoration.

UTHR Faces Competitive PressureUnited Therapeutics generates most of its revenues from its treprostinil-based PAH therapies, including Tyvaso, Orenitram, Adcirca and Remodulin. The company markets two versions of Tyvaso: Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. The drug remains the company's biggest growth driver, with the more convenient Tyvaso DPI continuing to gain traction and posting 9% year-over-year sales growth in the first quarter of 2026.

A key concern for United Therapeutics is the increasing competitive pressure on its core PAH franchise. While Tyvaso DPI continues to grow, sales of nebulized Tyvaso have been declining due to market erosion following the loss of exclusivity in May 2025 and the FDA approval of Liquidia Corporation’s (LQDA - Free Report) Yutrepia, the first inhaled dry-powder competitor for PAH and PH-ILD. Yutrepia's rapid market adoption, with 44% sequential sales growth in the first quarter of 2026, underscores the growing competitive threat to Tyvaso products.

UTHR’s heavy reliance on the PAH market remains a risk as its established therapies face rising competition from generics and newer treatments. With limited diversification beyond PAH, United Therapeutics' long-term growth depends largely on the successful development and commercialization of its pipeline, making any clinical, regulatory or commercialization setbacks a potential headwind for the stock.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Amarin Corporation (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.47. Over the same period, EPS estimates for 2027 have risen from $10.23 to $10.79. NBIX shares have lost 25.6% year to date.

Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.

Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 8.5% year to date.

Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.

July 09, 2026 16:10 ET  | Source: California Water Service Group

SAN JOSE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) today announced that its 2026 second-quarter earnings results will be released at 9:00 a.m. ET with its earnings conference call to follow at 11:00 a.m. ET on Thursday, July 30, 2026.

All stockholders and interested investors are invited to attend the conference call. To attend, please dial 1-800-715-9871 or 1-646-307-1963 and key in ID# 5478283, or you may access the live audio webcast at https://edge.media-server.com/mmc/p/p8cvrm58/

Please join at least 15 minutes in advance to ensure a timely connection to the call. A replay of the call will be available from 2:00 p.m. ET on Thursday, July 30, 2026, through September 28, 2026, at 1-800-770-2030 or 1-609-800-9909 and key in ID# 5478283, or by accessing the webcast above. The call will be hosted by Chairman, President and Chief Executive Officer Martin A. Kropelnicki and Senior Vice President, Chief Financial Officer and Treasurer James P. Lynch. Prior to the call, Cal Water will furnish a slide presentation on its website.

About California Water Service Group

California Water Service Group is the parent company of regulated utilities California Water Service, Hawaii Water Service, New Mexico Water Service, Washington Water Service, and Texas Water Service, a utility holding company. Together, these companies provide regulated and non-regulated water and wastewater service to more than 2.2 million people in California, Hawaii, New Mexico, Texas, and Washington. California Water Service Group’s common stock trades on the New York Stock Exchange under the symbol “CWT.” Additional information is available online at www.calwatergroup.com.

CONTACT:Jim Lynch, [email protected], (408) 367-8200
Shannon Dean, [email protected], (408) 367-8243  

July 09, 2026 16:05 ET  | Source: Crane NXT

WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT), a global leader in authentication and traceability technologies, today announced its schedule for the company’s second quarter 2026 results.

Earnings Release: Wednesday, August 5, 2026, after close of market by public distribution. To access the earnings release, please visit the Investors section of Crane NXT’s website at www.cranenxt.com.   Earnings Call: Thursday, August 6, 2026, at 10:00 a.m. Eastern Time. To access the webcast, please visit the Investors section of Crane NXT’s website at www.cranenxt.com. The archived webcast will be available on the company’s website.
About Crane NXT, Co.
Crane NXT is a global leader in authentication and traceability technologies that secure, detect, and authenticate what matters most to its customers. Through its two market-leading business segments, Security & Authentication Technologies and Detection & Traceability Technologies, Crane NXT provides innovative solutions that prevent the counterfeiting of products and identities and ensure the quality, authenticity, and traceability of products across the supply chain. Crane NXT’s approximately 6,000 employees help its customers protect their most important assets and ensure secure, seamless transactions around the world every day. For more information visit www.cranenxt.com.

Investors:

Matt Roache
VP, Investor Relations
[email protected]
www.cranenxt.com

, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026.

On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. 

Conference Call Details

The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q2-2026.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Investors:
Conor McNamara
+1.858.291.6421
[email protected] 

Media:
Christine Douglass
[email protected]

SOURCE Illumina, Inc.

Key Takeaways PNC is expanding through FirstBank and other deals, strengthening its market reach and revenue base.PNC benefits from solid capital, liquidity and an 18% dividend hike after the 2026 Fed stress test.PNC targets long-term growth through branch expansion, though expenses and commercial loans remain risks. The PNC Financial Services Group, Inc. (PNC - Free Report) shares have gained 14.3% in the past six months, outperforming the industry’s growth of 7.2%. Its close peers, Citigroup Inc. (C - Free Report) , have gained 16.7%, whereas shares of Wells Fargo (WFC - Free Report) have lost 9.9% during the same time period.

Price Performance
Image Source: Zacks Investment Research

Can PNC shares continue gaining after their recent strength? Let’s take a closer look.

What’s Aiding PNC’s Performance?Business Expansion Through Strategic Acquisitions: PNC Financial has been actively expanding its business through strategic acquisitions and partnerships to strengthen its market presence and diversify its revenue base. In January 2026, the company acquired FirstBank Holding Company, substantially expanding its franchise in Colorado and Arizona. The acquisition added 95 branches and $26.8 billion in assets, with management expecting the deal to contribute nearly $1 per share to earnings by 2027. Further, the successful conversion of 780,000 FirstBank customers, more than 1,620 employees and all 95 branches in June 2026 marked the completion of a major integration milestone.

Beyond expanding its banking footprint, PNC Financial has continued to enhance its product offerings and investment banking capabilities. In August 2025, it acquired Aqueduct Capital Group to strengthen the fund placement capabilities of Harris Williams. In 2024, the company partnered with Plaid to facilitate secure customer data sharing and expanded its alliance with TCW Group to offer private credit solutions to middle-market companies. These strategic initiatives are expected to support revenue diversification and drive long-term growth.

Solid Liquidity and Capital Strength Drive Shareholder Value: The company maintains a solid liquidity and capital position. As of March 31, 2026, its total available liquidity (comprising cash and due from banks, and interest-earning deposits in banks) was $31.7 billion, while long-term debt totaled $63.9 billion, with no short-term borrowings. Further, in June 2026, PNC cleared the Federal Reserve’s 2026 stress test, with its Common Equity Tier 1 (CET1) ratio of 10.1% comfortably exceeding its stress capital buffer-based regulatory requirement of 7%. Backed by this capital strength, the company raised its quarterly common stock dividend by 18% to $2 per share in July 2026.

Over the past five years, PNC has increased its dividend six times, delivering a five-year annualized dividend growth rate of 6%. Further, its current dividend yield of 2.76% compares favorably with the industry's average of 1.66%.

Dividend Yield
Image Source: Zacks Investment Research

Likewise, its peers, WFC and C, also announced plans to increase dividends following the 2026 Fed’s stress test. Wells Fargo intends to raise its third-quarter 2026 common stock dividend by 11% to 50 cents per share, subject to board approval, while Citigroup plans to increase its quarterly common stock dividend by 12% to 67 cents per share beginning in the third quarter of 2026, subject to quarterly board approval.

Apart from regular dividend hikes, PNC also returns capital through share repurchases. The company has an existing authorization to repurchase up to 100 million common shares, with nearly 32 million shares remaining under the program as of March 31, 2026. Given its strong liquidity and capital position, PNC's capital deployment initiatives appear sustainable and are expected to continue enhancing shareholder value.

Steady Growth in Loans and Deposits: The company continues to benefit from steady growth in its loan and deposit balances, supported by a strong balance sheet and strategic expansion initiatives. Its total loans and deposits recorded a compound annual growth rate (CAGR) of 5.5% and 7.3%, respectively, between 2019 and 2025. The growth momentum continued in the first quarter of 2026, with both loan and deposit balances increasing year over year. The acquisition of FirstBank further strengthened the company's balance sheet, adding nearly $16 billion in loans and $23 billion in deposits during the quarter. Earlier, in 2023, PNC Financial acquired approximately $16 billion of loan commitments from Signature Bank, enhancing its lending capacity.

Looking ahead, a well-diversified deposit base, continued growth in commercial and operational deposits and a relatively favorable interest rate environment are expected to support loan demand. Reflecting these tailwinds, management expects average loan balances to grow nearly 11% year over year in 2026, up from its earlier expectation of about 8% growth.

Expansion of Branch Network: PNC Financial continues to invest in its retail banking franchise through an aggressive branch expansion strategy. In November 2025, the company increased its planned investment in branch expansion to nearly $2 billion from the $1.5 billion announced in 2024. The initiative includes opening more than 300 branches across nearly 20 U.S. markets, renovating its entire branch network by 2029 and hiring more than 2,000 employees by 2030.

The company's focus on expanding in high-growth markets has already supported customer acquisition and checking account growth. Going forward, the expanded branch network is expected to strengthen PNC Financial's retail banking presence, deepen customer relationships and support sustainable revenue growth.

Few Concerns Prevail for PNCPersistent Expense Pressure: PNC Financial continues to witness an increase in operating expenses. The company's non-interest expenses recorded a CAGR of 4.6% between 2019 and 2025, with the upward trend continuing in the first quarter of 2026. While the company exceeded its 2025 Continuous Improvement Program cost-saving target, merger integration costs and continued investments in technology, branch expansion and personnel are expected to keep expenses elevated in the near term.

Total Expense Trend
Image Source: Zacks Investment Research

Loan Portfolio Concentration: The company's loan portfolio remains heavily concentrated in commercial lending. As of March 31, 2026, commercial loans accounted for 70% of total loans. Despite a diversified commercial portfolio, persistent weakness in office real estate and an uncertain macroeconomic environment remain concerns. Commercial loans accounted for 61.5% of total non-performing loans and 47.4% of net charge-offs as of March 31, 2026. Further, management expects commercial real estate charge-offs, particularly in the office segment, to remain elevated, posing risks to asset quality if economic conditions weaken.

Parting Thoughts on PNCPNC Financial's strategic acquisitions, expanding branch network, steady loan and deposit growth and solid liquidity position are expected to support its long-term financial performance.

Over the past week, the Zacks Consensus Estimate for 2026 earnings per share has been revised upward, while the estimate for 2027 has been revised downward.

Estimate Revision Trend
Image Source: Zacks Investment Research

The expected estimates imply growth of 13.5% and 11.4% for 2026 and 2027, respectively.

However, persistent expense pressure and the company's significant exposure to commercial lending remain key near-term headwinds. Additionally, the Fed's signal of a possible rate hike later in 2026 might put additional pressure on asset quality.

From a valuation perspective, PNC stock appears inexpensive relative to the industry. It is currently trading at a forward 12-month price-to-earnings (P/E) multiple of 12.36X, below the industry's 14.67X. Meanwhile, Wells Fargo and Citigroup trade at P/E multiples of 11.51X and 11.73X, respectively.

Price-to-Earnings F12 M
Image Source: Zacks Investment Research

Investors already holding the stock may consider retaining their positions, given PNC Financial's diversified growth initiatives, solid liquidity profile and sustainable capital deployment strategy. Those considering fresh investments may prefer to wait for a more favorable entry point until there is greater clarity on expense trends and commercial credit quality.

Currently, PNC Financial carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 

The move reflects ResMed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare.

• ResMed stock is showing downward pressure. What should traders watch with RMD?

The divestiture also strengthens ResMed’s ability to reallocate capital and resources toward innovation, operational scale, and long-term value creation across its connected, home-based care ecosystem.

MatrixCare Business and Financial ImpactMatrixCare provides software solutions to more than 15,000 providers and supports skilled nursing; senior living and long-term care; life planning communities and home health and hospice care.

The transaction is expected to close during the first quarter of ResMed’s fiscal year 2027.

Based on preliminary financial results for the full fiscal year 2026, the MatrixCare business represented approximately $220 million of revenue and approximately $55 million of adjusted operating profit.

In addition to the MatrixCare business-related financial considerations, ResMed’s recently completed Noctrix acquisition is expected to contribute approximately $30 million of revenue and reduce adjusted earnings by approximately 20 cents per share in fiscal year 2027.

ResMed continues to expect its Residential Care Software segment to accelerate to high single-digit percentage year-over-year revenue growth, along with operating leverage, in fiscal year 2027.

William Blair Sees Long-Term Benefit Despite Near-Term EPS DilutionWilliam Blair on Thursday wrote that, “even after buybacks, the deal will likely still be somewhat dilutive to EPS, but the sale of MatrixCare will divest an underperforming asset that created investor concerns around the durability of growth.”

Analyst Brandon Vazquez’s estimate suggests MatrixCare contributed about 29 cents to EPS.

While management has not disclosed the deal’s EPS impact, it plans to use the proceeds for an accelerated share repurchase program to return capital to shareholders.

The transaction’s effect on fiscal 2027 EPS remains uncertain, and we currently forecast 10% EPS growth for the year.

“We suspect investors will still want to see improving results from here, but we think this is a solid first step in improving the results in a key category for ResMed,” wrote Vazquez.

William Blair maintains an Outperform rating.

Noctrix Acquisition Supports ResMed’s Growth StrategyIn June, ResMed acquired Noctrix Health for $340 million.

Noctrix, an Angelini Ventures portfolio company, focuses on sleep health and respiratory care.

Angelini Ventures invested in Noctrix Health in 2024 as part of the company’s $40 million Series C financing round.

RMD Stock Price Activity: ResMed shares were up 0.94% at $207.81 at the time of publication on Thursday, according to Benzinga Pro data.

Photo by B..Robinson via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.